Journal article
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
Abstract
BACKGROUND: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown.
METHODS: Patients with atrial fibrillation and a moderate-to-high risk of stroke were randomly assigned, in a 1:1:1 ratio, to receive subcutaneous injection of abelacimab (150 mg or 90 mg once …
Authors
Ruff CT; Patel SM; Giugliano RP; Morrow DA; Hug B; Kuder JF; Goodrich EL; Chen S-A; Goodman SG; Joung B
Journal
The New England Journal of Medicine, Vol. 392, No. 4, pp. 361–371
Publisher
Massachusetts Medical Society
Publication Date
January 23, 2025
DOI
10.1056/nejmoa2406674
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralAntibodies, Monoclonal, HumanizedAnticoagulantsAtrial FibrillationDouble-Blind MethodFactor Xa InhibitorsFactor XIHemorrhageInjections, SubcutaneousRivaroxabanStrokeIncidenceSeverity of Illness IndexFollow-Up StudiesTreatment Outcome